Cargando…

Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application

Despite recent advances in the management of ovarian cancer, it remains the most lethal gynecologic malignancy. Vascular endothelial growth factor (VEGF) has been shown to play a pivotal role in the progression of ovarian cancer leading to the eventual development of malignant ascites. On this basis...

Descripción completa

Detalles Bibliográficos
Autores principales: Amini, Afshin, Masoumi Moghaddam, Samar, Morris, David L., Pourgholami, Mohammad H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180777/
https://www.ncbi.nlm.nih.gov/pubmed/21961001
http://dx.doi.org/10.1155/2012/540791
_version_ 1782212694114304000
author Amini, Afshin
Masoumi Moghaddam, Samar
Morris, David L.
Pourgholami, Mohammad H.
author_facet Amini, Afshin
Masoumi Moghaddam, Samar
Morris, David L.
Pourgholami, Mohammad H.
author_sort Amini, Afshin
collection PubMed
description Despite recent advances in the management of ovarian cancer, it remains the most lethal gynecologic malignancy. Vascular endothelial growth factor (VEGF) has been shown to play a pivotal role in the progression of ovarian cancer leading to the eventual development of malignant ascites. On this basis, agents rendering VEGF ineffective by neutralizing VEGF (bevacizumab), blocking its receptors (aflibercept), or interfering with the postreceptor signaling pathways (sunitinib) provide us with the rational treatment options. These agents are generally used in combination with the standard chemotherapeutic drugs. Here, we discuss the basis of and the logic behind the use of these agents in the treatment of epithelial ovarian cancer, as well as their evaluation in different preclinical and clinical studies.
format Online
Article
Text
id pubmed-3180777
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-31807772011-09-29 Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application Amini, Afshin Masoumi Moghaddam, Samar Morris, David L. Pourgholami, Mohammad H. J Oncol Review Article Despite recent advances in the management of ovarian cancer, it remains the most lethal gynecologic malignancy. Vascular endothelial growth factor (VEGF) has been shown to play a pivotal role in the progression of ovarian cancer leading to the eventual development of malignant ascites. On this basis, agents rendering VEGF ineffective by neutralizing VEGF (bevacizumab), blocking its receptors (aflibercept), or interfering with the postreceptor signaling pathways (sunitinib) provide us with the rational treatment options. These agents are generally used in combination with the standard chemotherapeutic drugs. Here, we discuss the basis of and the logic behind the use of these agents in the treatment of epithelial ovarian cancer, as well as their evaluation in different preclinical and clinical studies. Hindawi Publishing Corporation 2012 2011-09-26 /pmc/articles/PMC3180777/ /pubmed/21961001 http://dx.doi.org/10.1155/2012/540791 Text en Copyright © 2012 Afshin Amini et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Amini, Afshin
Masoumi Moghaddam, Samar
Morris, David L.
Pourgholami, Mohammad H.
Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application
title Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application
title_full Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application
title_fullStr Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application
title_full_unstemmed Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application
title_short Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application
title_sort utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180777/
https://www.ncbi.nlm.nih.gov/pubmed/21961001
http://dx.doi.org/10.1155/2012/540791
work_keys_str_mv AT aminiafshin utilityofvascularendothelialgrowthfactorinhibitorsinthetreatmentofovariancancerfromconcepttoapplication
AT masoumimoghaddamsamar utilityofvascularendothelialgrowthfactorinhibitorsinthetreatmentofovariancancerfromconcepttoapplication
AT morrisdavidl utilityofvascularendothelialgrowthfactorinhibitorsinthetreatmentofovariancancerfromconcepttoapplication
AT pourgholamimohammadh utilityofvascularendothelialgrowthfactorinhibitorsinthetreatmentofovariancancerfromconcepttoapplication